Fucosterol, a sterol extracted from Sargassum fusiforme, shows antidepressant and anticonvulsant effects

Zhen, Xing-Hua; Quan, Ying-Chun; Jiang, Haiying; Wen, Zheng-Shun; Qu, Youle; Guan, Liping

doi:10.1016/j.ejphar.2015.10.041

Cited by 57 publications

(41 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, 23 (20 mg/kg b.w.) administration to Balb/e mice reduced immobility time in the forced swim test, which is a measure of depression, by 82.2 s, a value very similar to that obtained with the positive control, fluoxetine, at the same concentration (85.1 s) [153]. The same effect was observed in the tail suspension test, where both fucosterol 23 and fluoxetine (20 mg/kg b.w.)…”

Section: Fucosterolsupporting

confidence: 74%

“…significantly increased serotonin, norepinephrine, and the metabolite 5-hydroxyindole acetic acid in the mouse brain, with levels very close to that observed in the brain of mice not subjected to the stress of the tail suspension and forced swimming tests. This suggests that the effects of fucosterol 23 may be mediated through these neurotransmitters [153]. Also, a significant increase in hippocampal brain-derived neurotrophic factor (BDNF) levels was found in the fucosterol 20 mg/kg (b.w.)…”

Section: Fucosterolmentioning

confidence: 97%

“…Also, a significant increase in hippocampal brain-derived neurotrophic factor (BDNF) levels was found in the fucosterol 20 mg/kg (b.w.) group, which suggests that the antidepressant effect may be mediated by increasing central BDNF levels [153].…”

Section: Fucosterolmentioning

confidence: 99%

See 2 more Smart Citations

Seaweed Secondary Metabolites with Beneficial Health Effects: An Overview of Successes in In Vivo Studies and Clinical Trials

et al. 2019

View full text Add to dashboard Cite

Macroalgae are increasingly viewed as a source of secondary metabolites with great potential for the development of new drugs. In this development, in vitro studies are only the first step in a long process, while in vivo studies and clinical trials are the most revealing stages of the true potential and limitations that a given metabolite may have as a new drug. This literature review aims to give a critical overview of the secondary metabolites that reveal the most interesting results in these two steps. Phlorotannins show great pharmaceutical potential in in vivo models and, among the several examples, the anti-dyslipidemia activity of dieckol must be highlighted because it was more effective than lovastatin in an in vivo model. The IRLIIVLMPILMA tridecapeptide that exhibits an in vivo level of activity similar to the hypotensive clinical drug captopril should still be stressed, as well as griffithsin which showed such stunning results over a variety of animal models and which will probably move onto clinical trials soon. Regarding clinical trials, studies with pure algal metabolites are scarce, limited to those carried out with kahalalide F and fucoxanthin. The majority of clinical trials currently aim to ascertain the effect of algae consumption, as extracts or fractions, on obesity and diabetes.Studies focusing on the preparation of macroalgae extracts and their chemical characterization revealed a large range of seaweed compounds with very interesting biological activities including antitumor, anti-inflammatory, antimicrobial, antidiabetic, antivirus, antihypertensive, fat-lowering, and neuroprotective activities [12][13][14][15].The large volume of studies proving the seaweed compound activities in in vitro systems [16][17][18][19] hints the need for further advancements in the knowledge about macroalgae compound efficiency in living systems (in vivo) and their use in the development of pharmaceuticals. In vitro studies are very relevant and yield very important information, but they only represent the first step of a long process, and the results obtained rarely reveal anything about the effects of a compound in vivo, because the responses observed in vitro can be magnified, diminished, or totally different in a more complex and integrated system. In fact, in vivo studies and clinical trials are those which contribute most to truly understanding the real potential of compounds as future pharmaceuticals.In this regard, the present work intends to present insight into the results obtained in the last few years regarding secondary metabolites, such as phlorotannins, halogenated compounds, fucoxanthin, and fucosterol isolated from macroalgae, involved in in vivo studies and clinical trials, identifying the research opportunities and knowledge gaps, to valorize these compounds and their natural resources. The intention is not to present an exhaustive survey of all published works, but rather a selection of authors based on the following criteria: in-depth studies involving pure compounds most characteristic f...

show abstract

Section: Fucosterolsupporting

confidence: 74%

Section: Fucosterolmentioning

confidence: 97%

See 1 more Smart Citation

Seaweed Secondary Metabolites with Beneficial Health Effects: An Overview of Successes in In Vivo Studies and Clinical Trials

et al. 2019

View full text Add to dashboard Cite

show abstract

“…From S. fusiforme , fucosterol [50,51], both C-24 epimers of saringosterol 2 [51] and 55 – 59 were isolated [51]. Fucosterol was shown to possess antidepressant and anticonvulsional effects [50].…”

Section: Structural Characterization and Biological Activitymentioning

confidence: 99%

“…Fucosterol was shown to possess antidepressant and anticonvulsional effects [50]. Compounds 55 – 59 , fucosterol, and both C-24 epimers of saringosterol 2 were tested as LXR (liver X receptor) agonists: 24 S -saringosterol 2 acted as a selective LXRβ agonist and was found to be potentially useful as a natural cholesterol lowering agent [51].…”

Section: Structural Characterization and Biological Activitymentioning

confidence: 99%

Secondary Metabolites and Biological Activity of Invasive Macroalgae of Southern Europe

et al. 2018

View full text Add to dashboard Cite

In this review a brief description of the invasive phenomena associated with algae and its consequences on the ecosystem are presented. Three examples of invasive algae of Southern Europe, belonging to Rodophyta, Chlorophyta, and Phaeophyta, were selected, and a brief description of each genus is presented. A full description of their secondary metabolites and biological activity is given and a summary of the biological activity of extracts is also included. In Asparagopsis we encounter mainly halogenated compounds. From Caulerpa, several terpenoids and alkaloids were isolated, while in Sargassum, meroterpenoids prevail.

show abstract

Therapeutic and nutraceutical potentials of a brown seaweed Sargassum fusiforme

Liu

Luthuli

Yang

et al. 2020

Food Science & Nutrition

View full text Add to dashboard Cite

show abstract

Fucosterol, a sterol extracted from Sargassum fusiforme, shows antidepressant and anticonvulsant effects

Cited by 57 publications

References 44 publications

Seaweed Secondary Metabolites with Beneficial Health Effects: An Overview of Successes in In Vivo Studies and Clinical Trials

Seaweed Secondary Metabolites with Beneficial Health Effects: An Overview of Successes in In Vivo Studies and Clinical Trials

Secondary Metabolites and Biological Activity of Invasive Macroalgae of Southern Europe

Therapeutic and nutraceutical potentials of a brown seaweed Sargassum fusiforme

Contact Info

Product

Resources

About